In the latest move to handle a continuing problem, Noven Pharmaceuticals announced Monday morning the voluntary recall of two lots containing several hundred thousand Daytrana patches, which are used to treat the symptoms of attention deficit hyperactivity disorder.

As with previous recalls, the problem concerns patients having difficulty removing the liner to expose the adhesive or attaching the patch to their skin.

In June, the company voluntarily recalled two other lots of several hundred thousand patches. In September, there was a recall of 22 lots.

The recall is being handled by Shire Limited, which is licensed to distribute the patch, which was developed and manufactured by Noven, based near Metrozoo in South Miami-Dade.

''This is a small fraction of Noven's monthly production,'' Noven spokesman Joe Jones said Monday. ``It is important to emphasize that all Daytrana patches, including those affected by this voluntary recall, can continue to be used unless the release liner can't be removed or the patches are damaged while being opened.''

Peter Brandt, Noven's chief executive officer, said in a prepared statement: ``We are committed to resolving the release liner issue. We have identified what we believe is the definitive root cause and are aggressively testing potential solutions that we expect will address the issue.

``As previously indicated, however, until testing is completed and solutions are implemented, voluntary actions like today's two lot recall are possible, as we work to assure that patients and caregivers can use Daytrana with the convenience they expect from this novel ADHD treatment.''

More information on the recall is available at daytrana.com.

Later on Monday, Jefferies & Co. issued an updated report on Noven, saying ``yet another Daytrana recall dims the outlook for that drug. We maintain our Underperform.''

However, Jefferies' analysists noted that a new agreement with Procter & Gamble Pharmaceuticals to develop a testosterone patch to increase women's sexual desire ``provides clarity. . . . Thus far, we have assigned little value to this product. Further progress may warrant a re-evaluation.''

In early afternoon trading on Monday, Noven's stock was down 34 cents, or 2.7 percent, trading at $12.34.

Join the discussion

Note: If this is your first time using our NEW commenting system, you will have to LOG OUT and then LOG BACK IN.

The Miami Herald is pleased to provide this opportunity to share information, experiences and observations about what's in the news. Some of the comments may be reprinted elsewhere in the site or in the newspaper. We encourage lively, open debate on the issues of the day, and ask that you refrain from profanity, hate speech, personal comments and remarks that are off point. In order to post comments, you must be a registered user of MiamiHerald.com. Your username will show along with the comments you post. Thank you for taking the time to offer your thoughts.

     Showing: Oldest first Newest first Most-recommended first Least-recommended first

@Nyx.AuthorDisplayName@ wrote on @Nyx.PostedAtTime@:

@Nyx.CommentBody@

@Nyx.Recommender@ @Nyx.AbuseReporter@